These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 31202268)
1. Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report. Casulari LA; de Castro LF; Kessler IM; Mendonça JL; de Fátima Magalhães Gonzaga M J Med Case Rep; 2019 Jun; 13(1):183. PubMed ID: 31202268 [TBL] [Abstract][Full Text] [Related]
2. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up. de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263 [TBL] [Abstract][Full Text] [Related]
3. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report. Koguchi M; Nakahara Y; Ebashi R; Ogata A; Shimokawa S; Masuoka J; Abe T J Med Case Rep; 2019 Jan; 13(1):18. PubMed ID: 30660191 [TBL] [Abstract][Full Text] [Related]
4. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy. Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004 [TBL] [Abstract][Full Text] [Related]
5. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene? Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630 [TBL] [Abstract][Full Text] [Related]
6. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602 [TBL] [Abstract][Full Text] [Related]
7. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080 [TBL] [Abstract][Full Text] [Related]
8. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771 [TBL] [Abstract][Full Text] [Related]
9. Medical Management of a Prolactinoma in a 15-Year-Old Girl. Bowling MS; Zamudio A; Jaffery F J Pediatr; 2018 Sep; 200():287-287.e1. PubMed ID: 29685620 [No Abstract] [Full Text] [Related]
10. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Shimon I; Benbassat C; Hadani M Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412 [TBL] [Abstract][Full Text] [Related]
13. Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study. Portari LHC; Correa-Silva SR; Abucham J Neuroendocrinology; 2022; 112(1):68-73. PubMed ID: 33477154 [TBL] [Abstract][Full Text] [Related]
14. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Hu J; Zheng X; Zhang W; Yang H Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765 [TBL] [Abstract][Full Text] [Related]
15. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature. Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167 [TBL] [Abstract][Full Text] [Related]
17. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma. Dhanwal DK; Sharma AK Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817 [TBL] [Abstract][Full Text] [Related]
18. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy. Kim D; Ku CR; Kim K; Jung H; Lee EJ Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105 [TBL] [Abstract][Full Text] [Related]
19. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature. Tng EL; Teo AE; Aung AT J Med Case Rep; 2023 Mar; 17(1):96. PubMed ID: 36927797 [TBL] [Abstract][Full Text] [Related]
20. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]